Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Malignant Gastric Outlet Obstruction
Interventions
Surgical gastrojejunostomy (S-GJ), EUS-guided gastrojejunostomy (EUS-GJ)
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Completed Not applicable Interventional Results available

EUS-GE vs ES for Palliation of Gastric Outlet Obstruction

NCT03259763
Conditions
Gastric Outlet Obstruction
Interventions
Lumen-apposing metal stent, Self-expandable metal stent
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Winston-Salem, North Carolina
Conditions
Hypertrophic Pyloric Stenosis
Interventions
Laparoscopic pyloromyotomy
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 12 Weeks
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG, High-grade Astrocytoma NOS, CNS Primary Tumor, NOS (Malignant Glioma)
Interventions
INCB7839
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Conditions
Catheter-related Bloodstream Infection (CRBSI) Nos, Bloodstream Infection Due to Central Venous Catheter, Bloodstream Infection Due to Hickman Catheter
Interventions
Ethanol, Heparin Lock, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Gastric Foreign Body, Nos, Disorder of Abdomen (Disorder), Foreign Body in Esophagus, Prostatic Diseases, Disease of Small Intestine
Interventions
Natural Orifice Transluminal Endoscopic Surgery (NOTES), Natural Orifice Translumenal Endoscopic Surgery (NOTES)
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Results available

Changes in Cerebral Oxygenation During Laparoscopic Pyloromyotomy

NCT03650842
Conditions
Pyloric Stenosis
Interventions
Near infrared spectroscopy (NIRS)
Device
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Emesis
Interventions
ad lib feedings after pyloromyotomy, FLAP diet after pyloromyotomy
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Day to 3 Months
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Advanced Cancer, Various, NOS
Interventions
BMS-833923, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 5 more
Conditions
Pyloric Stenosis
Interventions
Acetaminophen
Drug
Lead sponsor
Arlyne Thung
Other
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Interventions
SGR-1505
Drug
Lead sponsor
Schrödinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more
Not yet recruiting Phase 1 Interventional

Axatilimab + CAR-T for High-Risk Lymphoma

NCT07638982
Conditions
Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), High-Grade B-Cell Lymphoma, Nos, PMBCL, Follicular Grade 3 Lymphoma
Interventions
Axatilimab
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
8 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos
Interventions
Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection, Temozolomide, Tumor Tissue Sample, Blood Sample, Cerebrospinal Fluid (CSF) Sample
Radiation · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 5 more
Conditions
Gastro-Intestinal Cancer
Interventions
5-FU, Leucovorin, Irinotecan, Brivanib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
20 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Dallas, Texas • Temple, Texas
Terminated Phase 1Phase 2 Interventional Results available

Multiple Ascending Dose of BMS-911543

NCT01236352
Conditions
Cancer
Interventions
BMS-911543
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Houston, Texas
Conditions
Pyloric Stenosis
Interventions
Children with pyloric stenosis, Children without pyloric stenosis
Behavioral
Lead sponsor
Maimonides Medical Center
Other
Eligibility
2 Weeks to 9 Weeks
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
TAS1553
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 5 more
Conditions
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
XmAb13676
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 7 more
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

NCT05583149
Conditions
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Interventions
ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
Drug
Lead sponsor
Patrick C. Johnson, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Melanoma, Ovarian Cancer, Sarcoma, Bone, CNS-Spinal CD/MEMBR, NOS, Lymph Nodes, Soft Tissue
Interventions
IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in 3 fractions
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Conditions
Diffuse Large-cell B-cell Lymphoma
Interventions
Plamotamab, Tafasitamab, Lenalidomide
Biological · Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
Interventions
Telemedicine, Genetic Testing, Internet-Based Intervention, Educational Intervention, Patient Navigation, Interview, Survey Administration
Other · Behavioral
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
313
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 228 more
Conditions
Gastric Outlet Obstruction
Interventions
Surgical gastrojejunostomy (SGJ), Endoscopic gastrojejunostomy (EGJ)
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New Brunswick, New Jersey • Manhasset, New York • New Hyde Park, New York + 1 more